Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Feb. 27, 2025 — Perovskite solar cells could last ten times longer thanks to new research, which suggests alumina nanoparticles significantly enhance the lifespan and stability of these high ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Meanwhile, the Claude Code has been an early product but has been an asset for test-driven development, debugging complex ...

“These projects are key priorities for Novo and the team are eagerly awaiting the results from geological and geochemical sampling campaigns, expected in mid-March 2025, that will allow us to ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

So you shouldn't have to put up with poor service. Our annual energy satisfaction survey covers 16 suppliers in Great Britain. Our most recent results were published in January 2025 based on nearly 12 ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B0.99%increase; green up pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...

Shares of Alibaba surged 14% in Hong Kong and climbed 4% in pre-market trading in the US, following the company’s announcement that it would invest “aggressively” in artificial intelligence (AI) over ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. The Danish pharma giant ...